Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.77 |
| ▸ | RAB9A | P51151 | 8/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.77 |
| ▸ | MAPT | P10636 | 6/20 | 0.77 |
| ▸ | TP53 | P04637 | 5/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.76 |
| ▸ | CHRNA5 | P30532 | 3/20 | 0.76 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.76 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.73 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.73 |
| ▸ | RELA | Q04206 | 2/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
| ▸ | CA9 | Q16790 | 2/20 | 0.70 |
| ▸ | PPARA | Q07869 | 3/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2463534 | 0.87 | SMN1; SMN2 (0.93) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL1422890 | 0.87 | CHRNB2 (1.00) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL3430263 | 0.86 | NPC1 (0.79) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL1423272 | 0.85 | CHRNB2 (0.71) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL20370632 | 0.84 | SMN1; SMN2 (1.00) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL1422602 | 0.84 | NPC1 (0.77) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| Hydrochloric Acid SCHEMBL2273713 | 0.84 | CHRNB2 (0.69) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL3685718 | 0.82 | CHRNB2 (0.83) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL16592554 | 0.82 | NR1H4 (0.78) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL11323465 | 0.82 | NR1H4 (0.78) | NPC1RAB9ASMN1; SMN2MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | claimed |
| EP-4304630-A1 | SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM | Research Triangle Institute (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192126-A1 | SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM | RESEARCH TRIANGLE INSTITUTE (US) | 2022-09-15 | — | — | WO | disclosed |
| US-7112595-B2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| US-4065563-A | 3-Hetero-5-isothiocyanophenyl oxadiazoles as antifungal and antibacterial agents | E. R. SQUIBB & SONS, INC. (US) | 1977-12-27 | — | — | US | disclosed |
| US-4022901-A | FUNGICIDAL AND BACTERICIDAL ACTIVITY | E. R. SQUIBB & SONS, INC. (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | NPC1 941/4885RAB9A 1813/4885SMN1; SMN2 1279/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | NPC1 941/4885RAB9A 1813/4885SMN1; SMN2 1279/4885 |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | NPC1 941/4885RAB9A 1813/4885SMN1; SMN2 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.